Abstract 4441
Background
Cryo is an effective intervention for palliation and local control for small primary and metastatic tumours in mRCC. Pre-clinical murine tumour modeling found cryo recruits effector immune cells and synergizes with anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) to inhibit tumour rechallenge as compared to either therapy (tx) alone, leading to a prospective pilot study evaluating safety/tolerability.
Methods
NCT02626130 randomized pts to treme (CTLA-4) 10mg/kg every 4 weeks alone (arm A) or after cryo (arm B) for two doses followed by surgery (sx) or biopsy (bx) followed by maintenance treme. Best confirmed responses (ORR) were defined using RECIST v1.1, toxicity (tox) tabulated using CTCAE v4 with ≥ grade 3 adverse events (AE) possibly related reported, and time on study was defined as event free survival (EFS). Immune monitoring data (IMD): tissue based IHC, CyTOF, and RNA Nanostring.
Results
30 pts accrued, 29 pts received tx on study. More patients in Arm B had intermediate and poor risk disease as per IMDC criteria and had received >1 line of treatment as compared to Arm A leading to an imbalance between arms. Toxicity on study was similar between arms with six patients on each arm requiring treatment discontinuation due to AEs. IMD found clear cell histology (CC) had an inflamed tumor microenvironment (TME) with increased immune infiltration (IC) post treme in both arms compared to non-clear cell (NCC). CyTOF analysis identified an activated CD4+ T cell cluster expressing ICOS in the TME of CC pts compared to NCC.
Conclusions
Cryo+treme was tolerated similar to treme alone. IMD found a differential TME response to treme in CC vs NCC pts and in EFS >3 mo vs EFS <3 mo. Longer follow up is needed to determine impact of cryo in clinical efficacy endpoints.Table:
963P
Arm A n = 14 | Arm B n = 15 | |
---|---|---|
Histology Clear cell (CC) Non-clear cell (NCC) | 9 5 | 9 6 |
IMDC Good (CC/NCC) Intermediate Poor | 4 (4/0) 9 (5/4) 1 (0/1) | 0 11 (6/5) 4 (3/1) |
Prior nephrectomy | 7 (50%) | 5 (33%) |
Prior treatment 0 1 >1 | 10 2 2 | 10 0 5 |
Tissue collected | 6 sx, 4 bx, 4 no tissue | 5 sx, 4 bx, 6 NT |
ORR All (CC/NCC) PR SD PD Not measurable | 0 9 (7/2) 3 (2/1) 2 (0/2) | 1 (1/0) 4 (3/1) 5 (1/4) 5 (4/1) |
EFS mo (Arm A v Arm B) | 4.9 vs 3.2 (HR 0.73, 95%CI 0.35-1.58) | |
EFS mo (CC v NCC) | 3.3 vs 2.9 (HR 1.16, HR 95%CI 0.54-2.51) | |
EFS > 6 mo, #pts, (range) | Arm A: 4 (7.6-29.9), Arm B: 3 (6.3-30.3) | |
EFS> 6 mo (range) CC v NCC | CC: 4 (11.7-30.3), NCC 3 (6.3-7.8) |
Clinical trial identification
NCT02626130.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AztraZeneca.
Disclosure
M.T. Campbell: Honoraria (self): Pfizer; Honoraria (self): Genentech; Honoraria (self): Apricity Health LLC; Advisory / Consultancy: EMD Serono, Inc; Advisory / Consultancy: Genentech, Inc. E. Jonasch: Research grant / Funding (self), Research grant / Funding (institution): Exelixis; Research grant / Funding (self), Research grant / Funding (institution): Novartis; Research grant / Funding (self), Research grant / Funding (institution): Peloton; Research grant / Funding (self), Research grant / Funding (institution): Pfizer; Honoraria (self): Eisai; Honoraria (self): Exelixis; Honoraria (self): Genentech; Honoraria (self): Ipsen; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): Roche. A.Y. Shah: Honoraria (self): Eisai; Honoraria (self): Oncology Information Group; Honoraria (self): Roche Pharmaceuticals; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): BMS; Research grant / Funding (institution): EMD Serono. All other authors have declared no conflicts of interest.
Resources from the same session
5056 - Phase 2 study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
5710 - Avelumab for advanced Merkel cell carcinoma in the Netherlands; a nationwide survey
Presenter: Sonja Levy
Session: Poster Display session 3
Resources:
Abstract
3152 - Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data
Presenter: Sandra D'Angelo
Session: Poster Display session 3
Resources:
Abstract
5715 - A Phase 2, Randomized Study of Nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and Stereotactic Body Radiation Therapy (SBRT) for Metastatic Merkel Cell Carcinoma (MCC, NCT03071406) – a preliminary report.
Presenter: Sungjune Kim
Session: Poster Display session 3
Resources:
Abstract
2854 - Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma
Presenter: Kalijn Bol
Session: Poster Display session 3
Resources:
Abstract
2928 - Immune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients
Presenter: Mathilde Saint-Ghislain
Session: Poster Display session 3
Resources:
Abstract
1235 - Incidence and survival of Uveal Melanoma occurring as single cancer versus its occurrence as a first or second primary neoplasm
Presenter: Ahmad Alfaar
Session: Poster Display session 3
Resources:
Abstract
3615 - Validation of a Clinicopathological and Gene Expression Profile (CP-GEP) Model for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
Presenter: Evalyn Mulder
Session: Poster Display session 3
Resources:
Abstract
1793 - External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the Surveillance, Epidemiology and End Results (SEER) Program
Presenter: Angelina Tjokrowidjaja
Session: Poster Display session 3
Resources:
Abstract
4278 - Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts).
Presenter: Ines Pires da Silva
Session: Poster Display session 3
Resources:
Abstract